Attovia reels in $105M from crossover investors to run multiple trials of I&I...
California biotech Attovia Therapeutics is back with a $105 million Series B just 11 months after unveiling with $60 million. The Fremont-based startup eyes a series of clinical trials in the crowded...
View ArticleClik here to view.
CytomX’s Amgen-partnered T cell engager yields mixed Phase 1 data
CytomX and Amgen’s T cell engager showed mixed efficacy signals in an early trial in advanced solid tumors, sending the biotech’s shares down 37% even as analysts defended the data. The Phase 1a...
View ArticleTakeda to revamp in multiyear quest, pivots CAR-NK therapy from cancer to...
Takeda is launching a broad, multiyear restructuring, CEO Christophe Weber announced on Thursday. The company also said it is shifting its Phase 2 CAR-NK therapy from oncology to autoimmune diseases....
View ArticleClik here to view.
Infectious disease biotech Bluejay raises $182M for hepatitis trials
California biotech Bluejay Therapeutics has secured a megaround to continue developing its treatment candidates for chronic hepatitis D and B. The $182 million Series C, disclosed Thursday morning,...
View ArticleClik here to view.
Freeline unveils early efficacy signal for Gaucher gene therapy: #ASGCT24
BALTIMORE — Four patients with Gaucher disease were able to stop their regular treatments after receiving a one-time infusion of a gene therapy developed by Freeline Therapeutics. The four patients...
View ArticleClik here to view.
Acelyrin's founding CEO steps down, company scraps earnings call
Shao-Lee Lin is stepping down as founding CEO of Acelyrin, a California drug developer that raised the largest biotech IPO in 2023 and subsequently ran into clinical hurdles with its lead immunology...
View ArticleRoyalty Pharma inks MS deal with ImmuNext; X4 sells its priority review voucher
Plus, news about Pacira Biosciences, Cassava Sciences, Merck, Monopar Therapeutics, Eli Lilly and Optinose: Royalty Pharma signs MS deal: The company will pay about $525 million in cash to buy the...
View ArticleInnovent says next-gen GLP-1 drug from Eli Lilly beats top diabetes med in...
A next-generation GLP-1 candidate from Eli Lilly has outdone an older Lilly drug in a Phase 3 trial involving Chinese patients with diabetes, Lilly partner Innovent announced late Wednesday. The...
View ArticleRapt Therapeutics winds down Phase 2 studies of lead candidate in wake of...
Rapt Therapeutics said it will close and unblind two mid-stage trials in atopic dermatitis and asthma after they were put on clinical hold earlier this year due to a case of liver failure. The company...
View ArticleNucleus RadioPharma makes Artbio’s radiopharma assets; Minaris manufactures...
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. CDMO Nucleus RadioPharma is partnering with clinical-stage company...
View ArticleClik here to view.
Charles River touts first-quarter manufacturing revenue, says China bill is...
Charles River Laboratories’ manufacturing arm delivered a large revenue jump in the first quarter of the year owing to an uptick in customer activity. James Foster The company also noted that it...
View ArticleVerona inks financing deal worth up to $650M ahead of COPD decision
Verona Pharma has secured up to $650 million to aid the potential launch of its COPD candidate ensifentrine. Under new agreements with Oaktree Capital Management and OMERS Life Sciences, Verona can...
View ArticleClik here to view.
Bluebird bio starts 15 patients on its three multimillion-dollar gene therapies
Bluebird bio’s stock $BLUE jumped over 20% on Thursday following its first-quarter earnings release and the announcement of 15 patients starting on its three approved gene therapies: Zynteglo, Skysona...
View ArticleClik here to view.
Across two clinical trials, gene therapy restores hearing in children deaf...
BALTIMORE — Ten out of 11 children who were born deaf can now hear after receiving a gene therapy from a Shanghai biotech, according to new results shared Thursday. The children who recovered their...
View ArticleAhead of likely approval, ICER finds Geron’s imetelstat is not cost-effective...
In the lead-up to the likely approval of Geron’s drug to treat certain types of anemia, drug pricing watchdog the Institute for Clinical and Economic Review said Thursday that the drug would not be...
View ArticleTakeda to shut down San Diego research center
Takeda is shuttering its San Diego research site, the company confirmed to Endpoints News. The company told employees on Thursday that it will close the site as part of a decision “to focus more of our...
View ArticleCorrected: Experts to decide within a year whether to recommend Duchenne...
An advisory committee has postponed its decision to decide whether Duchenne muscular dystrophy should be included in a federally-recommended newborn screening panel for up to one year, Parent Project...
View ArticleBIO CEO defends the organization's about-face on the Biosecure Act
As the head of the trade group BIO and a parent to children with a rare disease, John Crowley is personally and professionally at the center of a bill targeting Chinese biotechs. Under Crowley, BIO...
View ArticleAfter FTC scrutiny of Sanofi deal, Maze finds a new Pompe partner in Shionogi
Maze Therapeutics has found a new buyer for its Pompe disease candidate, five months after scrutiny from the Federal Trade Commission led Sanofi to back out of a deal for the clinical-stage drug. The...
View ArticleAGC Biologics to cut close to 4% of staffers 'to adjust business priorities'
CDMO AGC Biologics is laying off just under 4% of its workforce across its headquarters in Seattle, WA, a site in Boulder, CO, and “some supporting global functional areas,” a company spokesperson told...
View Article